DDInter1242 DDInter624
Montelukast was first approved for clinical use by the US FDA in 1998 as Merck's brand name Singulair. The medication is a member of the leukotriene receptor antagonist (LTRA) category of drugs.[L6301,L6304,L6307,L6310,L6325,L6328,L6331] Although capable of demonstrating effectiveness, the use of such LTRAs like montelukast is typically in addition to or complementary with the use of inhaled corticosteroids or other agents in asthma step therapy. Regardless, in 2008-2009, there were FDA-led investigations into the possibility of montelukast to elicit neuropsychiatric effects like agitation, hallucinations, suicidal behaviour, and others in individuals who used the medication. And although these kinds of effects are currently included in the official prescribing information for montelukast,[L6301,L6304,L6307,L6310,L6325,L632
Efavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1. For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen. Efavirenz is also used in combination with other antiretroviral agents as part of an expanded postexposure prophylaxis regimen to prevent HIV transmission for those exposed to materials associated with a high risk for HIV transmission.
Montelukast {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Efavirenz
Montelukast {u} (Compound) causes {v} (Side Effect) Hepatitis
Hepatitis {u} (Side Effect) is caused by {v} (Compound) Efavirenz
Montelukast {u} (Compound) treats {v} (Disease) chronic obstructive pulmonary disease
chronic obstructive pulmonary disease {u} (Disease) is associated with {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Efavirenz
Montelukast {u} (Compound) upregulates {v} (Gene) SESN1
SESN1 {u} (Gene) regulates {v} (Gene) POLR2I
POLR2I {u} (Gene) is downregulated by {v} (Compound) Efavirenz
Montelukast {u} (Compound) upregulates {v} (Gene) MCOLN1
MCOLN1 {u} (Gene) is regulated by {v} (Gene) POLR2I
POLR2I {u} (Gene) is downregulated by {v} (Compound) Efavirenz
Montelukast {u} (Compound) upregulates {v} (Gene) SESN1
SESN1 {u} (Gene) is regulated by {v} (Gene) IKBKB
IKBKB {u} (Gene) is upregulated by {v} (Compound) Efavirenz
Montelukast {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Aminoglutethimide
Aminoglutethimide {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Efavirenz
Montelukast {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dexamethasone
Dexamethasone {u} (Compound) binds {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is bound by {v} (Compound) Efavirenz
Montelukast {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Trimethoprim
Trimethoprim {u} (Compound) causes {v} (Side Effect) Hallucination
Hallucination {u} (Side Effect) is caused by {v} (Compound) Efavirenz
Montelukast {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Leflunomide
Leflunomide {u} (Compound) causes {v} (Side Effect) Hepatitis
Hepatitis {u} (Side Effect) is caused by {v} (Compound) Efavirenz
Montelukast (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Efavirenz (Compound)
Montelukast (Compound) causes Hepatitis (Side Effect) and Hepatitis (Side Effect) is caused by Efavirenz (Compound)
Montelukast (Compound) treats chronic obstructive pulmonary disease (Disease) and chronic obstructive pulmonary disease (Disease) is associated with CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Efavirenz (Compound)
Montelukast (Compound) upregulates SESN1 (Gene) and SESN1 (Gene) regulates POLR2I (Gene) and POLR2I (Gene) is downregulated by Efavirenz (Compound)
Montelukast (Compound) upregulates MCOLN1 (Gene) and MCOLN1 (Gene) is regulated by POLR2I (Gene) and POLR2I (Gene) is downregulated by Efavirenz (Compound)
Montelukast (Compound) upregulates SESN1 (Gene) and SESN1 (Gene) is regulated by IKBKB (Gene) and IKBKB (Gene) is upregulated by Efavirenz (Compound)
Montelukast may cause a moderate interaction that could exacerbate diseases when taken with Aminoglutethimide and Aminoglutethimide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Efavirenz (Compound)
Montelukast may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Efavirenz (Compound)
Montelukast may cause a moderate interaction that could exacerbate diseases when taken with Trimethoprim and Trimethoprim (Compound) causes Hallucination (Side Effect) and Hallucination (Side Effect) is caused by Efavirenz (Compound)
Montelukast may cause a moderate interaction that could exacerbate diseases when taken with Leflunomide and Leflunomide (Compound) causes Hepatitis (Side Effect) and Hepatitis (Side Effect) is caused by Efavirenz (Compound)